Champions Oncology Stock Revenue
| CSBR Stock | USD 4.32 0.23 5.05% |
Champions Oncology fundamentals help investors to digest information that contributes to Champions Oncology's financial success or failures. It also enables traders to predict the movement of Champions Stock. The fundamental analysis module provides a way to measure Champions Oncology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Champions Oncology stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 50.2 M | 52.7 M |
Champions | Revenue |
Champions Oncology Company Revenue Analysis
Champions Oncology's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Champions Oncology Revenue | 50.16 M |
Most of Champions Oncology's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Champions Oncology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Champions
Projected quarterly revenue analysis of Champions Oncology provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Champions Oncology match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Champions Oncology's stock price.
Champions Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Champions Oncology is extremely important. It helps to project a fair market value of Champions Stock properly, considering its historical fundamentals such as Revenue. Since Champions Oncology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Champions Oncology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Champions Oncology's interrelated accounts and indicators.
| 0.96 | 0.97 | 0.18 | 0.63 | 0.52 | ||
| 0.96 | 0.99 | 0.27 | 0.7 | 0.6 | ||
| 0.97 | 0.99 | 0.21 | 0.64 | 0.52 | ||
| 0.18 | 0.27 | 0.21 | 0.04 | 0.19 | ||
| 0.63 | 0.7 | 0.64 | 0.04 | 0.69 | ||
| 0.52 | 0.6 | 0.52 | 0.19 | 0.69 |
Click cells to compare fundamentals
Champions Revenue Historical Pattern
Today, most investors in Champions Oncology Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Champions Oncology's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Champions Oncology revenue as a starting point in their analysis.
Champions Oncology Revenue |
| Timeline |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Champions Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Champions Oncology reported 50.16 M of revenue. This is 99.34% lower than that of the Life Sciences Tools & Services sector and 93.25% lower than that of the Health Care industry. The revenue for all United States stocks is 99.47% higher than that of the company.
Champions Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Champions Oncology's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Champions Oncology could also be used in its relative valuation, which is a method of valuing Champions Oncology by comparing valuation metrics of similar companies.Champions Oncology is currently under evaluation in revenue category among its peers.
Champions Oncology Current Valuation Drivers
We derive many important indicators used in calculating different scores of Champions Oncology from analyzing Champions Oncology's financial statements. These drivers represent accounts that assess Champions Oncology's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Champions Oncology's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 91.4M | 141.0M | 101.4M | 65.8M | 65.7M | 46.0M | |
| Enterprise Value | 86.9M | 145.9M | 101.8M | 64.3M | 70.5M | 44.4M |
Champions Oncology ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Champions Oncology's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Champions Oncology's managers, analysts, and investors.Environmental | Governance | Social |
Champions Oncology Institutional Holders
Institutional Holdings refers to the ownership stake in Champions Oncology that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Champions Oncology's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Champions Oncology's value.| Shares | Bank Of New York Mellon Corp | 2024-06-30 | 26.7 K | State Street Corp | 2024-06-30 | 26.6 K | Bank Of America Corp | 2024-06-30 | 25.3 K | Cambridge Invest Research Advisors, Inc. | 2024-09-30 | 12.3 K | Mesirow Fin Investmt Mgmt Intl Equity | 2024-09-30 | 12 K | Stifel Financial Corp | 2024-06-30 | 10.9 K | Citadel Advisors Llc | 2024-06-30 | 10.2 K | Simplex Trading, Llc | 2024-06-30 | 3 K | Ubs Group Ag | 2024-06-30 | 379 | Battery Management Corp | 2024-09-30 | 2.4 M | Nea Management Company, Llc | 2024-06-30 | 1.7 M |
Champions Fundamentals
| Return On Equity | -4.32 | ||||
| Return On Asset | -0.0693 | ||||
| Profit Margin | (0.07) % | ||||
| Operating Margin | 0.09 % | ||||
| Current Valuation | 62.94 M | ||||
| Shares Outstanding | 13.59 M | ||||
| Shares Owned By Insiders | 26.33 % | ||||
| Shares Owned By Institutions | 50.64 % | ||||
| Number Of Shares Shorted | 189.5 K | ||||
| Price To Earning | 220.00 X | ||||
| Price To Book | 6.77 X | ||||
| Price To Sales | 1.12 X | ||||
| Revenue | 50.16 M | ||||
| Gross Profit | 24.34 M | ||||
| EBITDA | (5.05 M) | ||||
| Net Income | (7.28 M) | ||||
| Cash And Equivalents | 8.06 M | ||||
| Cash Per Share | 0.60 X | ||||
| Total Debt | 7.43 M | ||||
| Debt To Equity | 1.03 % | ||||
| Current Ratio | 1.11 X | ||||
| Book Value Per Share | (0.02) X | ||||
| Cash Flow From Operations | (6.14 M) | ||||
| Short Ratio | 16.30 X | ||||
| Earnings Per Share | (0.26) X | ||||
| Target Price | 6.0 | ||||
| Number Of Employees | 210 | ||||
| Beta | 0.49 | ||||
| Market Capitalization | 58.05 M | ||||
| Total Asset | 26.13 M | ||||
| Retained Earnings | (84.59 M) | ||||
| Working Capital | (7.9 M) | ||||
| Current Asset | 4.34 M | ||||
| Current Liabilities | 5.31 M | ||||
| Net Asset | 26.13 M |
About Champions Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Champions Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Champions Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Champions Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Champions Oncology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Champions Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Champions Oncology will appreciate offsetting losses from the drop in the long position's value.Moving against Champions Stock
The ability to find closely correlated positions to Champions Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Champions Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Champions Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Champions Oncology to buy it.
The correlation of Champions Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Champions Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Champions Oncology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Champions Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Champions Stock Analysis
When running Champions Oncology's price analysis, check to measure Champions Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Champions Oncology is operating at the current time. Most of Champions Oncology's value examination focuses on studying past and present price action to predict the probability of Champions Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Champions Oncology's price. Additionally, you may evaluate how the addition of Champions Oncology to your portfolios can decrease your overall portfolio volatility.